← Back to headlines
Acadia outlines 2026 revenue target up to $1.28B while advancing DAYBUE STIX and NUPLAZID growth
Acadia Pharmaceuticals has set a 2026 revenue target of up to $1.28 billion, driven by the advancement of DAYBUE STIX and NUPLAZID growth initiatives.
26 Feb, 06:58 — 26 Feb, 06:58
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Romania Posts January Budget Surplus Amid Spending Restraints
2m ago
Athens Stock Exchange Focuses on Corporate Earnings, Dividends, and MSCI Rebalancing
3m ago
EBRD cuts forecast for Romania’s economy to 1.2% growth this year, followed by 2.2% in 2027
8m ago
Nigeria's Non-Interest Sector Expands with ₦1bn Ethical Fund Launch
14m ago